News articles about Ampliphi Biosciences Corp (NYSE:APHB) have been trending somewhat positive on Wednesday, according to Accern. The research firm scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ampliphi Biosciences Corp earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 46.82800911633 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Shares of Ampliphi Biosciences Corp (NYSE:APHB) traded down 2.4634% on Wednesday, reaching $0.7998. The company had a trading volume of 84,356 shares. The company’s 50-day moving average price is $1.97 and its 200 day moving average price is $1.02. The firm’s market capitalization is $5.30 million. Ampliphi Biosciences Corp has a 52 week low of $0.30 and a 52 week high of $38.25.

ILLEGAL ACTIVITY NOTICE: “Ampliphi Biosciences Corp (APHB) Receiving Somewhat Favorable Press Coverage, Report Shows” was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at

About Ampliphi Biosciences Corp

AmpliPhi Biosciences Corporation is a biotechnology company. The Company is focused on the discovery, development and commercialization of phage therapeutics. The Company is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products.

Receive News & Ratings for Ampliphi Biosciences Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampliphi Biosciences Corp and related companies with's FREE daily email newsletter.